R
Rosella Silvestrini
Researcher at University of Modena and Reggio Emilia
Publications - 230
Citations - 7615
Rosella Silvestrini is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 45, co-authored 229 publications receiving 7450 citations.
Papers
More filters
Journal ArticleDOI
Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More
Gianni Bonadonna,Umberto Veronesi,Cristina Brambilla,Laura Ferrari,Alberto Luini,Marco Greco,Cesare Bartoli,Gianfranco Coopmans de Yoldi,Roberto Zucali,Franco Rilke,Salvatore Andreola,Rosella Silvestrini,Giovanni Di Fronzo,Pinuccia Valagussa +13 more
TL;DR: The results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity.
Journal ArticleDOI
The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients
Rosella Silvestrini,Silvia Veneroni,Maria Grazia Daidone,E. Benini,Patrizia Boracchi,Maura Mezzetti,Giovanni Di Fronzo,Franco Rilke,Umberto Veronesi +8 more
TL;DR: The predictive role of Bcl-2 expression on 6-year relapse-free and overall survival was mainly dependent on p53 expression.
Journal ArticleDOI
p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients
Rosella Silvestrini,E. Benini,Maria Grazia Daidone,Silvia Veneroni,Patrizia Boracchi,Vera Cappelletti,G. Di Fronzo,Umberto Veronesi +7 more
TL;DR: Immunohistochemically detected p53 overexpression is an independent marker for shortened 6-year relapse-free and overall survival in node-negative patients with resectable breast cancers and should be used with other established prognostic factors, such as [3H]thymidine labeling index and estrogen receptor status, to further refine the prognostic assessment of node- negative breast cancer.
Journal ArticleDOI
‘Daunomycin’, a New Antibiotic of the Rhodomycin Group
A Dimarco,M Gaetani,P Orezzi,B M Scarpinato,Rosella Silvestrini,M Soldati,T. Dasdia,L Valentini +7 more
TL;DR: ‘DAUNOMYCIN’ is a new antibiotic isolated from the cultures of S. peucetius1 in the Farmitalia Research Laboratories and is easily obtained as hydrochloride in thin red needles melting at 184°–186° C.
Journal ArticleDOI
Cell kinetics as a prognostic marker in node-negative breast cancer.
TL;DR: The relevance of cell kinetics of the primary tumor as a marker of biologic aggressivity was verified on a series of 258 patients with operable breast cancer without nodal and distant metastases who underwent radical mastectomy, showing the relevance of the kinetic variable as an important prognostic marker in breast cancer.